share_log

We Like The Quality Of Medtronic's (NYSE:MDT) Earnings

We Like The Quality Of Medtronic's (NYSE:MDT) Earnings

我們喜歡美敦力(紐交所:MDT)收益的質量
Simply Wall St ·  12/06 19:06

Medtronic plc's (NYSE:MDT) solid earnings announcement recently didn't do much to the stock price. We did some digging, and we think that investors are missing some encouraging factors in the underlying numbers.

美敦力(紐交所:MDT)最近發佈的穩健盈利公告對股票價格影響不大。我們進行了調查,認爲投資者忽視了底層數據中一些鼓舞人心的因素。

big
NYSE:MDT Earnings and Revenue History December 6th 2024
紐交所:MDT 每股收益和營業收入歷史 2024年12月6日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

To properly understand Medtronic's profit results, we need to consider the US$996m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Medtronic to produce a higher profit next year, all else being equal.

要正確理解美敦力的盈利結果,我們需要考慮與飛凡項目相關的99600萬美元的費用。看到飛凡項目讓公司損失利潤並不好,但從積極的一面來看,情況可能會很快改善。我們查看了數千家上市公司,發現飛凡項目往往是一次性的。而且,畢竟,這正是會計術語所暗示的。假設這些飛凡費用不會再次出現,我們因此預計美敦力明年的利潤會更高,其他條件相同。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Medtronic's Profit Performance

我們對美敦力盈利表現的看法

Because unusual items detracted from Medtronic's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Medtronic's earnings potential is at least as good as it seems, and maybe even better! And the EPS is up 6.7% over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for Medtronic and you'll want to know about it.

由於飛凡項目影響了美敦力去年收益的表現,因此可以說我們可以期待本季度的表現有所改善。因爲這個原因,我們認爲美敦力的盈利潛力至少和看起來的一樣好,甚至更好!每股收益在過去十二個月上漲了6.7%。本文的目標是評估我們在多大程度上可以依賴法定收益來反映公司的潛力,但還有很多其他因素需要考慮。鑑於此,如果您想對公司進行更多分析,了解相關風險是至關重要的。您會感興趣的是,我們發現了美敦力的一個警告信號,您需要了解一下。

This note has only looked at a single factor that sheds light on the nature of Medtronic's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這篇文章僅關注了一個因素,揭示了美敦力利潤的性質。但還有很多其他方式可以幫助您形成對公司的看法。有些人認爲較高的股本回報率是高質量業務的良好標誌。因此,您可能想查看這份高股本回報率企業的免費集合,或者查看這份內部持股比例高的股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論